Revance’s $260 Million China Market License Agreement with Fosun Pharma for RT002

Michael Patrini

O’Melveny represented Silicon Valley-based biotechnology company Revance Therapeutics, Inc. in a licensing agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Michael Patrini

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here